JPMorgan Chase & Co. Lowers Position in Smith & Nephew plc (NYSE:SNN)


Share on StockTwits

JPMorgan Chase & Co. lowered its holdings in Smith & Nephew plc (NYSE:SNN) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 378,405 shares of the medical equipment provider’s stock after selling 1,387 shares during the period. JPMorgan Chase & Co. owned approximately 0.09% of Smith & Nephew worth $15,958,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. WCM Investment Management LLC raised its holdings in shares of Smith & Nephew by 2.0% in the 4th quarter. WCM Investment Management LLC now owns 7,566,531 shares of the medical equipment provider’s stock valued at $319,081,000 after acquiring an additional 146,660 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Smith & Nephew by 8.4% in the 4th quarter. Northern Trust Corp now owns 2,149,494 shares of the medical equipment provider’s stock valued at $90,644,000 after acquiring an additional 167,224 shares in the last quarter. FMR LLC raised its holdings in shares of Smith & Nephew by 640.8% in the 1st quarter. FMR LLC now owns 1,341,034 shares of the medical equipment provider’s stock valued at $53,788,000 after acquiring an additional 1,160,015 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Smith & Nephew by 13.4% in the 4th quarter. Wells Fargo & Company MN now owns 781,823 shares of the medical equipment provider’s stock valued at $32,969,000 after acquiring an additional 92,414 shares in the last quarter. Finally, Prio Wealth Limited Partnership increased its position in shares of Smith & Nephew by 1.3% during the 4th quarter. Prio Wealth Limited Partnership now owns 590,963 shares of the medical equipment provider’s stock valued at $24,921,000 after purchasing an additional 7,832 shares during the last quarter. 8.91% of the stock is currently owned by hedge funds and other institutional investors.

SNN opened at $38.55 on Tuesday. The stock’s 50 day simple moving average is $38.53 and its 200 day simple moving average is $40.27. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.18 and a quick ratio of 1.04. Smith & Nephew plc has a 1 year low of $34.29 and a 1 year high of $46.10. The firm has a market cap of $16.94 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 4.91 and a beta of 0.70.

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 12th. Investors of record on Tuesday, April 6th will be given a dividend of $0.462 per share. This represents a yield of 1.8%. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.28. The ex-dividend date is Monday, April 5th. Smith & Nephew’s dividend payout ratio (DPR) is presently 44.12%.

Several equities analysts have recently commented on the company. Berenberg Bank reiterated a “buy” rating on shares of Smith & Nephew in a research report on Tuesday, February 23rd. Sanford C. Bernstein upgraded Smith & Nephew from a “market perform” rating to an “outperform” rating and set a $46.50 price objective on the stock in a research report on Friday, December 18th. Commerzbank lowered Smith & Nephew from a “buy” rating to a “hold” rating in a research report on Monday, February 22nd. Barclays reiterated an “overweight” rating on shares of Smith & Nephew in a research report on Wednesday, March 31st. Finally, Credit Suisse Group reiterated a “neutral” rating on shares of Smith & Nephew in a research report on Monday, February 22nd. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $47.17.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

Recommended Story: Do investors pay a separate front-end load every time they buy additional shares?

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.